The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine [Oncovin] may be limited in certain areas of the country. We understand this news is very concerning to patients who receive this medicine and their…
The U.S. Food and Drug Administration (FDA) requested the voluntary recall from Allergan in reference to the company’s Biocell textured implants linked to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). According to the Agency, Allergan agreed and is removing these…
On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech, Biogen) for the treatment of CD20-positive non-Hodgkin B-cell Lymphoma (NHL) and chronic lymphocytic…
On June 10, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after at least two prior…
On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with rituximab (RITUXAN, Genentech, Inc.) for the treatment of adult patients with relapsed or refractory follicular…
On May 24, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. The approval was…
New York (May 15, 2019) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of venetoclax (VENCLEXTA, AbbVie Inc. and Genentech, Inc.) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic…
New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This…